One key element is the anticipated Phase 3 MAPLE-HCM data, expected in the first half of 2025, which is seen as a critical catalyst for aficamten’s expanded use. The drug aims to become the ...

Cytokinetics should hear back from the FDA next September about its marketing application for aficamten, which is vying to become the first rival to Bristol-Myers Squibb's fast-growing Camzyos for ...

Cytokinetics (CYTK) announced that Sanofi (SNY) will acquire exclusive rights to develop and commercialize aficamten from Corxel Pharmaceuticals for the treatment of patients with obstructive and ...

The financial terms of the deal were not discosed. Aficamten is an investigational selective, small molecule cardiac myosin inhibitor for the potential treatment of patients with HCM. CORXEL ...

Stifel analyst James Condulis writes Cytokinetics’ aficamten is an exceptional drug as it sets a strong competitive standard for a multi-billion-dollar obstructive hypertrophic cardiomyopathy ...